Olema Pharmaceuticals (OLMA) Insider Trading & Ownership $4.20 +0.06 (+1.45%) Closing price 04:00 PM EasternExtended Trading$4.24 +0.04 (+1.07%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Olema Pharmaceuticals (NASDAQ:OLMA) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage19.40%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$1.73 MNumber OfInsiders Selling(Last 12 Months)5Amount OfInsider Selling(Last 12 Months)$42.15 M Get OLMA Insider Trade Alerts Want to know when executives and insiders are buying or selling Olema Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address OLMA Insider Buying and Selling by Quarter Remove Ads Olema Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails1/8/2025Bain Capital Life Sciences InvMajor ShareholderBuy300,000$5.76$1,728,000.00 12/17/2024G. Walmsley GrahamDirectorSell700,761$6.75$4,730,136.75 12/10/2024Cyrus HarmonDirectorSell8,256$9.37$77,358.72 12/10/2024David C MylesInsiderSell12,452$9.38$116,799.76 12/10/2024Sean BohenCEOSell52,328$9.37$490,313.36 8/1/2024Biocapital Advisors L ParadigmMajor ShareholderSell2,400,000$14.91$35,784,000.00 7/29/2024Cyrus HarmonDirectorSell4,066$15.58$63,348.28 7/11/2024Cyrus HarmonDirectorSell5,000$12.26$61,300.00 6/28/2024Cyrus HarmonDirectorSell20,000$10.77$215,400.00 6/3/2024Cyrus HarmonDirectorSell5,000$10.93$54,650.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 5/31/2024Cyrus HarmonDirectorSell15,000$9.41$141,150.00 5/6/2024Cyrus HarmonDirectorSell5,000$10.92$54,600.00 4/30/2024Cyrus HarmonDirectorSell15,000$9.51$142,650.00 3/28/2024Cyrus HarmonDirectorSell20,000$10.97$219,400.00 (Data available from 1/1/2013 forward) OLMA Insider Trading Activity - Frequently Asked Questions Who is on Olema Pharmaceuticals's Insider Roster? The list of insiders at Olema Pharmaceuticals includes Bain Capital Life Sciences Inv, Biocapital Advisors L Paradigm, Bvf Partners L P/Il, Cyrus Harmon, David C Myles, G. Walmsley Graham, Naseem Zojwalla, and Sean Bohen. Learn more on insiders at OLMA. What percentage of Olema Pharmaceuticals stock is owned by insiders? 19.40% of Olema Pharmaceuticals stock is owned by insiders. Learn more on OLMA's insider holdings. Which Olema Pharmaceuticals insiders have been buying company stock? The following insiders have purchased OLMA shares in the last 24 months: Bain Capital Life Sciences Inv ($1,728,000.00), Biocapital Advisors L Paradigm ($1,160,000.00), Bvf Partners L P/Il ($14,818,370.88), and G. Walmsley Graham ($1,871,235.30). How much insider buying is happening at Olema Pharmaceuticals? Insiders have purchased a total of 2,037,802 OLMA shares in the last 24 months for a total of $19,577,606.18 bought. Which Olema Pharmaceuticals insiders have been selling company stock? The following insiders have sold OLMA shares in the last 24 months: Biocapital Advisors L Paradigm ($35,784,000.00), Cyrus Harmon ($3,061,900.12), David C Myles ($483,348.03), G. Walmsley Graham ($4,730,136.75), Naseem Zojwalla ($110,721.24), and Sean Bohen ($926,193.20). How much insider selling is happening at Olema Pharmaceuticals? Insiders have sold a total of 3,501,218 Olema Pharmaceuticals shares in the last 24 months for a total of $45,096,299.34 sold. Olema Pharmaceuticals Key ExecutivesDr. Sean P. Bohen M.D. (Age 57)Ph.D., President, CEO & Director Compensation: $1.15MMr. Shane William Charles Kovacs M.B.A. (Age 50)Chief Operating & Financial Officer Compensation: $820.37kDr. Naseem Zojwalla M.D. (Age 51)Chief Medical Officer Compensation: $753.37kMs. Julie DexterSenior VP & Head of PeopleDr. David C. Myles Ph.D. (Age 61)Chief Discovery & Non-Clinical Development Officer Compensation: $200kMs. Demiana Faltaos Ph.D.Pharm.D., VP & Head of Clinical PharmacologyMr. John B. Moriarty Jr. (Age 56)ESQ., J.D., Corporate Secretary Compensation: $434.32kMs. Sasha Austin CPAVP of Finance & Controller More Insider Trading Tools from MarketBeat Related Companies NTLA Insider Selling RCUS Insider Selling VIR Insider Selling RCKT Insider Selling COLL Insider Selling XNCR Insider Selling REPL Insider Selling PAHC Insider Selling DAWN Insider Selling ZYME Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles NVIDIA Insiders Sell: This Is What It Means for the Market Top 3 Insider Stock Buys in March—Are They Still Good in April?Grocery Outlet Insider and Institutional Buyers Signal BottomSentinelOne Insider Selling? Why Investors Should Stay Bullish 3 Companies Buying Back Stock—Why It Matters This page (NASDAQ:OLMA) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Olema Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Olema Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
